Albuminuria, prevalent in heart failure (HF), independently predicts HF incidence and progression, yet its causes and mechanisms remain unclear. Despite being underutilized in cardiovascular trials, it emerges as a critical predictor of HF risk, especially when present alongside normal eGFR, suggesting its potential as an early indicator of cardiovascular and kidney disease. Incorporating albuminuria into HF risk prediction models may aid in forecasting HF development and targeting interventions to reduce albuminuria could potentially mitigate HF incidence and progression.

Albuminuria independently forecasts HF risk, but its full prognostic potential and therapeutic implications are not fully understood. Despite its underutilization in cardiovascular trials, its inclusion in HF risk prediction models could enhance risk assessment. Future research should explore interventions targeting albuminuria reduction and clarify its prognostic significance in different HF subgroups like HFpEF and HFrEF.

Reference: Khan MS, Shahid I, Anker SD, et al. Albuminuria and Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 Jan 24;81(3):270-282. doi: 10.1016/j.jacc.2022.10.028. PMID: 36653095.